The estimated pooled HR for all studies suggested that the risk of death was not associated with intraepithelial CD8+/CD4+ ratio in ovarian cancer patients (Supplementary Figure 5; HR, 0.48; 95%CI, 0.21-1.11; PHR=0.086; I2=81.7%; random effects model). Here, CD4 is linked to ovarian carcinoma.